Nesheim M
Department of Biochemistry, Queen's University, Kingston, Ontario, Canada.
Ital Heart J. 2001 Sep;2(9):641-5.
When fibrin deposition and removal are properly balanced, the organism is protected from both a catastrophic loss of blood at the site of injury and the inappropriate loss of fluidity within the vascular system. When these activities are not properly balanced, however, severe bleeding or thromboses can occur. Myocardial infarction is a common and morbid consequence of the latter. The thrombin/thrombomodulin complex plays an essential role in regulating this balance because it generates both an anticoagulant substance, activated protein C, and an antifibrinolytic substance, activated TAFI (thrombin activatable fibrinolysis inhibitor, also known as plasma carboxypeptidase B or carboxypeptidase U). Thus, the coagulation and fibrinolytic cascades are explicitly linked by virtue of thrombin catalyzed activation of TAFI, either by the thrombin/thrombomodulin complex or, in the absence of thrombomodulin, by the massive amounts of thrombin generated through the factor XI-dependent pathway after clotting. Some potential targets for diagnosis, prognosis and therapy related to the balance between fibrin formation and removal include: development of a convenient global assay for plasma fibrinolytic potential; an assay for plasma or urine thrombomodulin that had been oxidized at methionine 388 and thereby has lost its capacity to stimulate activation of protein C but not TAFI; an assay for activated TAFI; discovery of a means for tapping the tremendous potential of the vasculature to acutely release tissue-type plasminogen activator; and an assessment of the potential role of polymorphisms in the TAFI gene which might influence TAFI levels or the properties TAFIa. In addition, a much fuller and quantitative understanding of the properties of the coagulation and tibrinolytic cascades is needed in order to optimize diagnosis, prognosis and therapy in disorders such as myocardial infarction that are related to the balance between fibrin formation and removal.
当纤维蛋白的沉积和清除达到适当平衡时,机体可免受损伤部位血液的灾难性流失以及血管系统内流动性的不当丧失。然而,当这些活动失衡时,就可能发生严重出血或血栓形成。心肌梗死就是后者常见且严重的后果。凝血酶/血栓调节蛋白复合物在调节这种平衡中起着至关重要的作用,因为它既能产生一种抗凝物质——活化蛋白C,又能产生一种抗纤维蛋白溶解物质——活化TAFI(凝血酶激活的纤维蛋白溶解抑制剂,也称为血浆羧肽酶B或羧肽酶U)。因此,凝血和纤维蛋白溶解级联反应通过凝血酶催化的TAFI激活而明确关联,这一激活过程可由凝血酶/血栓调节蛋白复合物介导,或者在缺乏血栓调节蛋白的情况下,由凝血后通过因子XI依赖性途径产生的大量凝血酶介导。一些与纤维蛋白形成和清除平衡相关的诊断、预后和治疗潜在靶点包括:开发一种方便的血浆纤维蛋白溶解潜能整体检测方法;检测血浆或尿液中在蛋氨酸388处被氧化因而失去刺激蛋白C激活但不影响TAFI激活能力的血栓调节蛋白;检测活化TAFI;发现一种挖掘血管系统急性释放组织型纤溶酶原激活剂巨大潜能的方法;以及评估TAFI基因多态性可能影响TAFI水平或TAFIa特性的潜在作用。此外,为了优化与纤维蛋白形成和清除平衡相关疾病(如心肌梗死)的诊断、预后和治疗,需要对凝血和纤维蛋白溶解级联反应的特性有更全面和定量的了解。